Monte Rosa Therapeutics, Inc. (GLUE) vs SpyGlass Pharma, Inc. Common Stock (SGP)
A side-by-side comparison of Monte Rosa Therapeutics, Inc. and SpyGlass Pharma, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GLUE
Monte Rosa Therapeutics, Inc.
$9.85HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
SGP
SpyGlass Pharma, Inc. Common Stock
$25.13HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — GLUE vs SGP
growth of $100 · dividends reinvested · last 1yGLUE -47.5% (-47.5%/yr)SGP -3.1% (-3.1%/yr)SGP compounded faster over this window
GLUE SGP
GLUE vs SGP: by the numbers
- •SGP is the larger company ($840M vs $832M market cap).
- •Both run net losses; SGP's is the smaller (0.00% vs -560.85% net margin).
Metrics side by side
Valuation
| Metric | GLUE | SGP |
|---|---|---|
| P/S ratio | 28.97 | N/A |
| P/B ratio | 1.71 | 3.62 |
Profitability
| Metric | GLUE | SGP |
|---|---|---|
| Gross margin | 92.94% | 0.00% |
| Operating margin | -43.83% | 0.00% |
| Net margin | -560.85% | 0.00% |
| ROE | -33.06% | -24.12% |
| ROIC | -28.69% | -26.54% |
Growth (annualized)
| Metric | GLUE | SGP |
|---|---|---|
| Total return CAGR (5Y) | -12.32% | N/A |
Go deeper
Dig into the metrics
Monte Rosa Therapeutics ROESpyGlass Pharma, Inc. Common Stock ROEMonte Rosa Therapeutics operating marginSpyGlass Pharma, Inc. Common Stock operating marginMonte Rosa Therapeutics revenue growthSpyGlass Pharma, Inc. Common Stock revenue growthMonte Rosa Therapeutics free cash flowSpyGlass Pharma, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.